17β-HSD

Cat. No.

A69091

CAS No.

2758802-19-4

HSD17B13-IN-23

HSD17B13-IN-23 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and below 1 μM for leukotriene B3. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), particularly in relation to nonalcoholic steatohepatitis (NASH). Its capacity to modulate HSD17B13 activity makes it a valuable tool for investigating the biochemical pathways involved in hepatic lipid metabolism and related disorders.

Cat. No.

A69092

CAS No.

2770247-93-1

HSD17B13-IN-88

HSD17B13-IN-88 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤0.1 μM for estradiol. This compound selectively modulates steroid hormone metabolism and has significant implications for research in metabolic disorders and liver diseases. Its ability to influence estradiol levels makes it a valuable tool for studying hormone-related pathways and therapeutic strategies.

Cat. No.

A69093

CAS No.

2849338-46-9

HSD17B13-IN-99

HSD17B13-IN-99 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound demonstrates significant potential for investigating liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Researchers can utilize HSD17B13-IN-99 to explore therapeutic strategies and mechanisms related to these health issues.

Cat. No.

A69094

CAS No.

2919797-60-5

HSD17B13-IN-22

HSD17B13-IN-22 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound demonstrates significant biological activity in modulating lipid metabolism and is relevant in the study of liver-related disorders, including hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. Its application in research enables a deeper understanding of HSD17B13's role in these conditions, potentially paving the way for therapeutic advancements.

Cat. No.

A69095

CAS No.

2770247-20-4

HSD17B13-IN-60

HSD17B13-IN-60 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is primarily utilized in research related to liver and metabolic diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its inhibition of HSD17B13 makes it a valuable tool for understanding the underlying mechanisms of these disorders and developing potential therapeutic strategies.

Cat. No.

A69096

CAS No.

2758802-14-9

HSD17B13-IN-18

HSD17B13-IN-18 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for Leukotriene B3. This compound is significant in the context of nonalcoholic fatty liver diseases (NAFLDs), particularly in the study of nonalcoholic steatohepatitis (NASH). HSD17B13-IN-18 facilitates research aimed at understanding and potentially therapeutically targeting metabolic disorders related to liver function.

Cat. No.

A69097

CAS No.

10441-27-7

3-Acetyl-7-Hydroxycoumarin

3-Acetyl-7-Hydroxycoumarin is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). It exhibits significant biological activity, demonstrating 57% inhibition of 17β-HSD1 at a concentration of 6 μM. This compound is valuable for research applications focused on hormone-dependent diseases, including breast cancer and endometriosis.

Cat. No.

A69098

CAS No.

2848620-90-4

HSD17B13-IN-94

HSD17B13-IN-94 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is instrumental in the investigation of liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective inhibition of HSD17B13 provides valuable insights into the underlying mechanisms of these diseases.

Cat. No.

A69099

CAS No.

2770246-21-2

HSD17B13-IN-78

HSD17B13-IN-78 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in research focused on nonalcoholic fatty liver disease (NAFLD), aiding in the understanding of lipid metabolism and associated metabolic disorders. HSD17B13-IN-78 serves as an important tool for studying the therapeutic potential of targeting HSD17B13 in liver-related pathologies.

Cat. No.

A69100

CAS No.

1826337-40-9

S07-2005 (racemic)

S07-2005 (racemic) is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor, exhibiting an IC50 value of 0.13 μM for AKR1C3 and 0.75 μM for AKR1C4. This compound demonstrates significant potential as a chemotherapeutic potentiator, particularly in overcoming resistance mechanisms in cancer treatment. Its selectivity and efficacy make it a valuable tool for research applications focused on cancer biology and drug resistance mechanisms.

Cat. No.

A69102

CAS No.

2730027-86-6

HSD17B13-IN-36

HSD17B13-IN-36 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol as a substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), making it valuable for research concerning metabolic disorders and liver health. Its selective inhibition of HSD17B13 may provide insights into therapeutic interventions for liver-related diseases.

Cat. No.

A69103

CAS No.

2770247-76-0

HSD17B13-IN-85

HSD17B13-IN-85 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is primarily employed in the study of nonalcoholic fatty liver disease (NAFLD) and offers significant insights into the role of HSD17B13 in metabolic regulation and liver physiology. Its specific inhibition enhances understanding of the enzyme's contribution to various biological processes and potential therapeutic targets in liver-related disorders.

Cat. No.

A69105

CAS No.

2770247-73-7

HSD17B13-IN-84

HSD17B13-IN-84 is a potent inhibitor of the enzyme 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in research concerning nonalcoholic fatty liver disease (NAFLD), providing valuable insights into the role of HSD17B13 in lipid metabolism and liver pathophysiology. Its effective inhibition of HSD17B13 supports studies aimed at understanding disease mechanisms and potential therapeutic interventions.

Cat. No.

A69106

CAS No.

2849338-45-8

HSD17B13-IN-98

HSD17B13-IN-98 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), demonstrating an IC50 value for estradiol of less than 0.1 μM. This compound is particularly relevant in the investigation of nonalcoholic fatty liver disease, providing valuable insights into the biochemical pathways involved in lipid metabolism and liver function. Its specificity and efficacy make it an essential tool for research focused on metabolic disorders and related therapeutic strategies.

Cat. No.

A69107

CAS No.

2770247-11-3

HSD17B13-IN-59

HSD17B13-IN-59 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its specific mechanism of action makes it an essential tool in elucidating the role of HSD17B13 in various pathophysiological contexts.

Cat. No.

A69108

CAS No.

108530-10-5

7-Coumaryl triflate

7-Coumaryl triflate is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), demonstrating an IC₅₀ of 360 nM and a Kᵢ of 173 nM. This compound selectively targets 17β-HSD2 while displaying no significant affinity for estrogen receptors ERα or ERβ. 7-Coumaryl triflate is valuable for research focused on hormone-dependent breast cancer and the modulation of estrogen metabolism.

Cat. No.

A69109

CAS No.

2919797-61-6

HSD17B13-IN-26

HSD17B13-IN-26 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound exhibits significant activity in the modulation of steroid metabolism and demonstrates potential therapeutic applications in liver diseases, including hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. Researchers can utilize HSD17B13-IN-26 to further investigate the role of HSD17B13 in liver pathology and associated metabolic disorders.

Cat. No.

A69111

CAS No.

2589-71-1

4'-Hydroxyvalerophenone

Synonyms: 4-Pentanoylphenol; 4-Valerylphenol

4'-Hydroxyvalerophenone is a specific inhibitor of 17β-hydroxysteroid dehydrogenase (17β-HSD), exhibiting an IC50 value of 60.52 μM. This compound plays a significant role in steroid metabolism and can be utilized in various research applications related to hormonal regulation and steroid biosynthesis. Its inhibitory effects make it a valuable tool for studies investigating the role of 17β-HSD in physiological and pathological processes.

Cat. No.

A69112

CAS No.

243638-37-1

17β-HSD5 inhibitor 1

17β-HSD5 inhibitor 1 is a potent inhibitor of 17β-HSD5, demonstrating an IC50 of 2.9 nM in HEK-293 cells that overexpress human 17β-HSD5. This compound is primarily utilized in research applications related to steroid metabolism and is instrumental in studying the modulation of sex steroid biosynthesis. The selective inhibition of 17β-HSD5 can provide insights into its role in various hormonal disorders and therapeutic interventions.

Cat. No.

A69113

CAS No.

1106941-19-8

17β-HSD5 inhibitor 2

17β-HSD5 inhibitor 2 is a potent inhibitor of 17β-hydroxysteroid dehydrogenase 5 (17β-HSD5), demonstrating an IC50 value of 40 nM. This compound is valuable for research into steroid metabolism and androgen biosynthesis, with potential applications in studying conditions related to hormone regulation and prostate cancer. Its inhibitory action enables the exploration of therapeutic strategies targeting 17β-HSD5 in various biological contexts.

Cat. No.

A77869

CAS No.

2990549-76-1

Steroid sulfatase/17β-HSD1-IN-3

Steroid sulfatase/17β-HSD1-IN-3 is a potent dual inhibitor targeting steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). It irreversibly inhibits human STS activity with an IC50 of 27 nM, demonstrating significant efficacy. This compound is suitable for research focused on endometriosis and other estrogen-dependent diseases, facilitating the exploration of therapeutic strategies in these areas.

Cat. No.

A77876

CAS No.

2990549-70-5

Steroid sulfatase/17β-HSD1-IN-1

Steroid sulfatase/17β-HSD1-IN-1 is a potent inhibitor of steroid sulfatase and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), exhibiting an IC50 value of 28 nM for human steroid sulfatase in cellular assays. This compound is valuable for investigating estrogen-dependent diseases, making it an important tool for research in hormone-related therapeutic areas. Its specificity and potency support studies aiming to elucidate the role of these enzymes in disease mechanisms.

Cat. No.

A77877

CAS No.

2990549-94-3

Steroid sulfatase/17β-HSD1-IN-4

Steroid sulfatase/17β-HSD1-IN-4 is a potent dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). It irreversibly inhibits hSTS activity, demonstrating an IC50 value of 63 nM. This compound is valuable for studying endometriosis and other estrogen-dependent diseases, providing insights into the role of steroid metabolism in these conditions.

Cat. No.

B18131

CAS No.

2986319-18-8

S19-1035

S19-1035 is a selective inhibitor of aldo-keto reductase 1C3 (AKR1C3), exhibiting a potent inhibition with an IC50 of 3.04 nM. This compound is valuable for studying the role of AKR1C3 in tumor biology and its potential implications in oncological research. Researchers can utilize S19-1035 to investigate the mechanisms underlying tumor progression and to explore new therapeutic strategies targeting AKR1C3.